Clinical trials
Completed Phase 2 Lung Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 54 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 7 |
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| Merck Sharp & Dohme LLC | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Vertex Pharmaceuticals Incorporated | 2 |
| Altair Therapeutics, Inc. | 1 |
| Altesa Biosciences, Inc. | 1 |
| Altor BioScience | 1 |
| Augusta University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases | 54 |
| Respiratory Tract Diseases | 19 |
| Pulmonary Disease, Chronic Obstructive | 12 |
| Asthma | 8 |
| Lung Diseases, Obstructive | 8 |
| Cystic Fibrosis | 7 |
| Respiration Disorders | 7 |
| Bronchial Diseases | 6 |
| Pulmonary Fibrosis | 6 |
| Emphysema | 5 |
Trials
Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.